Results 161 to 170 of about 77,264 (275)

Validation, quantification, and molecular docking of isolated eupalitin 3-O-β-D-galactopyranoside in Boerhavia diffusa Linn for hepatoprotective and immunomodulatory activity. [PDF]

Sci Rep
Aldawsari HM, Ameena K, Thasneem CK, Binmahfouz LS, Ashri LY, Ahammed SYE, Uoorakkottil I.   +6 more
europepmc   +1 more source

Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies

MedComm, Volume 7, Issue 5, May 2026.
The mechanism of multiple signaling pathways and their related targeted inhibitors in HCC. (A) The mechanism of Ras/Raf/MEK/ERK signaling pathway and its related targeted inhibitors; (B) the mechanism of PI3K/AKT/mTOR signaling pathway and its crosstalk with other pathways and its related targeted inhibitors; (C) the mechanism of JAK/STAT signaling ...
Penghui He, Sinan Xie, Kunlin Xie, Fengwei Gao, Yunshi Cai, Yan Huang, Chang Liu, Hong Wu, Yinghao Lyu, Tian Lan   +9 more
wiley   +1 more source

Myo-Inositol: Pharmacokinetics, Biological Functions, and Therapeutic Potential in Liver Protection: Insights from Preclinical Models. [PDF]

Antioxidants (Basel)
Antonowski T, Osowski A, Wojtkiewicz J.
europepmc   +1 more source

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

Phytochemical Profiling and Pharmacoinformatics Reveal Proliverenol from <i>Phaleria macrocarpa</i> as a Multi-Target Hepatoprotective Modulator of MAFLD. [PDF]

Pharmaceuticals (Basel)
Nurkolis F, Dama A, Gorica E, Santini A, Tjandrawinata RR.   +4 more
europepmc   +1 more source

Investigating the Therapeutic Potential of Tamarix aphylla Leaf Extract Against Toxicity Caused by Graphene Nanosheets in Cirrhinus mrigala

Veterinary Medicine and Science, Volume 12, Issue 3, May 2026.
Tamarix aphylla leaf extract significantly alleviated graphene nanosheet–induced toxicity in Cirrhinus mrigala, reducing oxidative tissue damage and restoring organ integrity. Rich in antioxidant compounds, the extract offers a promising natural strategy for mitigating the biological impacts of graphene‐related pollutants.
Muhammad Asad, Kashif Ali, Tehseen Fatima, Nagina Rehman, Abeer Kazmi, Md. Fakhrul Islam, Aneela Nijabat, Asma Ashraf, Ihsan Ullah, Ayesha Siddiqa, Juan Pedro Luna‐Arias, Gabriela Medina‐Pérez, Amir Ali   +12 more
wiley   +1 more source

Role of tannin-rich plant fractions in hepatoprotection: a nanotechnology perspective. [PDF]

Discov Nano
Shende S, Patel J.
europepmc   +1 more source

Growth differentiation factor 15 mitigates lipotoxic steatosis by preserving mitochondrial morphodynamics and augmenting fatty acid oxidation in hepatocytes and liver organoids

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3788-3806, May 2026.
Abstract Aims Growth differentiation factor 15 (GDF15) has emerged as a promising metabolic regulator with hepatoprotective properties in metabolic dysfunction‐associated steatotic liver disease (MASLD), yet its underlying mechanisms remain elusive.
Jia Li, Qi Zhou, Mengmeng Xia, Yakun Li, Junyu Wang, Manon Buist‐Homan, Vincent E. de Meijer, Hans Blokzijl, Klaas Nico Faber, Han Moshage   +9 more
wiley   +1 more source

Bioactive polyphenols from <i>Isodon serra</i> with antioxidant and hepatoprotective activities <i>in vitro</i> and <i>in vivo</i>. [PDF]

RSC Adv
Li S, Huang Z, Lv L, Wang S, Yang G, Zhang L, Du M, Zhang Y, Ma J, Hong M, He X, Yang J.   +11 more
europepmc   +1 more source

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 766-780, May 2026.
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu, Ying Chun Lee, Yu‐Wei Fang, Wen‐Hui Hsieh, Ming‐Hsien Tsai   +4 more
wiley   +1 more source